Day 1 :
South University School of Pharmacy, USA
Time : 09:45-10:25
The turnaround of the millennium brought us lots of expectation in terms of world market globalization economy, planet environment preservation and energy resources to mention a few. However, one of the most important discoveries in the science field was the unveiling of the human genome. Since then, most of the attention has turned to understanding the function of many genes and genomic fragments and their relationship with human pathophysiology. Much has been accomplished so far, such as BRCA1 and BRCA2 markers for breast cancer; HOXB13 gene for prostate cancer; APOE ε4 for Alzheimer’s disease and many others that lead to the possibility of genetic testing to predict the risk of developing the disease, if the mutant variant gene is expressed in the individual genome.
Coffee is the mostly widely consumed beverage worldwide with known health benefits. The genomic approach to search for specific regions in the human DNA that are highly expressed within the coffee consumers is also a recent phenomenon. Genome-wide association studies (GWAS) have identified a number of regions of interest associated with coffee consumption. A consortium actually was created with the participation of researchers from all over the world, in an effort to accelerate these findings. The purpose is to understand the relationship between parts of the human DNA and the increased or decreased coffee use and its correlation with the prevention of a series of diseases as type-2 diabetes, cancers and neurodegenerative diseases that account for the majority of the chronic disorders that afflict our post-millennium population.
American University, USA
Time : 10:25-11:05
b-Lactams have historically been viewed as a class of antimicrobials. However, this paradigm is shifting towards a focus on their ability to function as inhibitors of bacterial enzymes, particularly those involved in broad-spectrum b-lactam resistance, i.e., extended spectrum b-lactamases (ESBL). This shift in focus is the result of the recognition of the b-lactam’s ability to acylate enzymes, the majority of which have serine as nucleophile in the active site. In addition to being inhibitors of bacterial enzymes, b-lactams also inhibit viral and mammalian serine enzymes demonstrating inter-kingdom activity. The focus of this presentation is on the evaluation of the potential of b-lactam antibiotics as inhibitors of the serine enzymes of both prokaryotic and eukaryotic origin, with specific focus on the structure-function relationship of b-lactams as antimicrobial and antineoplastic agents.